Skip to main content


Figure 1 | EJNMMI Research

Figure 1

From: Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with 68Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy

Figure 1

68Ga-DOTA-peptide uptake in PET and its comparison to enhancing tumor volume in MRI-T1-Gad. Time-activity curves show higher 68Ga-DOTA-peptide uptake in HGGs compared to skin but distinctly lower uptake when compared to pituitary gland (A). Tumor SUVmax at 30 to 60 min post-injection correlates to receptor binding potential (B) and to enhancing tumor volume in MRI-T1-Gad (C). However, PET and MRI-T1-Gad tumor volumes show apparent discordance in individual patients (D) (corresponding to patient numbers in Table 1).

Back to article page